Introduction
Regulation of cell proliferation is a complex process involving the regulated expression and/or modi®cation of discrete gene products. There is a growing list of evidence to support the involvement of paracrine growth inhibitors and intracellular growth suppressors in the regulation of cell growth. Representatives of these classes of molecules are secretory proteins like interferons (IFN), and cell cycle inhibitors like p21 WAF1 and p27
Kip1 that inhibit the cyclin-dependent kinases (CDKs). An obvious question is whether the growth inhibition by IFN is mediated through the pathway(s) that control the activation of CDKs.
Interferons (IFNs) are a family of hormone-like secretory proteins which interact with neighboring cells and bring about many phenotypical changes in these cells. Like most cytokines, IFNs must bind to speci®c high anity cellular receptors to exert biological eects. These eects include regulation of expression of speci®c genes, antiviral properties, and inhibition of cell growth and proliferation (Sokawa, 1977; Pestka et al., 1987; Kumar and Atlas, 1992; Kumar et al., 1994; Yamada et al., 1994; Tiefenbrum et al., 1996) . The inhibition of cell proliferation by IFNs is an active process, and generally involves arrest of cells in the G0/ G1-phase of the cell cycle. IFN-a and IFN-b have also been considered to have a natural negative regulatory role in the autocrine regulation of cell proliferation, as several growth factors induce the formation of IFN in the cells they stimulate (Zullo et al., 1985; Moore et al., 1984) , and this possibly could prevent uncontrolled cell proliferation. The mechanisms underlying growth inhibitory eects by IFNs are not well established.
The regulation of cell cycle is controlled by families of essential proteins which control transition between dierent stages of the cell cycle. These proteins either facilitate cell cycle progression or serve to break the progression. The cell cycle progression through the speci®c phases of the cell cycle is regulated by the sequential formation, activation and inactivation of a family of serine/threonine kinases, the CDKs (reviewed in Reed, 1992; Sherr, 1993; Hunter and Pine, 1994) . The CDKs are a family of enzymes that are inactive as monomers, and require association with cyclins for activation. The activities of CDK-4 and CDK-2 appear to be most critical to the restriction point transitions, particularly, passage through the G1-phase and entry into the S-phase (Hunter and Pine, 1994) . CDKcomplexes also associate with proliferating cell nuclear antigen (PCNA) to form a catalytically active kinase complex that phosphorylates retinoblastoma protein (pRB) (abrogate growth-inhibitory function of pRB). This allows release of transcription factor E2F, which activates the expression of target genes required in DNA synthesis (Reed, 1991; Dulic et al., 1992; Xiong et al., 1993) . The activity of CDKs is negatively controlled by CDK-inhibitors (CKIs) such as p21 WAF1 and p27
Kip1 . Both p21 WAF1 and p27 Kip1 have been shown to inhibit the activity of CDK-2-and CDK4-cyclin complex's in vitro (Xiong et al., 1993; Harper et al., 1993; Kato et al., 1994; Hall et al., 1995) . The p21 WAF1 has been shown to also bind to PCNA and block DNA replication (Waga et al., 1994) . It is believed that CKIs bind to cyclin/CDK complexes and set stoichiometric inhibitory thresholds of CDKs kinase activity, which prevents premature or inappropriate progression of the cell cycle by impeding their ability to phosphorylate target substrates such as pRB family proteins.
In addition to CKIs, the activity of CDKs is regulated by cycles of phosphorylation and dephosphorylation (reviewed in Clarke, 1995; Morgan, 1995) . One of the key phosphorylation event controlling CDKs activity is the activation of phosphorylation on a residue in various CDKs, corresponding to threonine (Thr) 161 in human prototypic CDK-1. Phosphorylation of this residue is positively required for function of both human and yeast CDK-1 and recent reports have shown that an analogous phosphorylation step is essential for activities of CDK-2 and CDK-4 (Poon et al., 1993; . A kinase responsible for phosphorylating the Thr 161 of CDK-1 and the corresponding residue in other CDKs (T 172 in CDK-4, T 160 in CDK-2) has been identi®ed in various organisms and designated CAK, for CDK-activating kinase (also known as CDK-7). The catalytic subunit of CDK-7 requires binding of a regulating cyclin H subunit to become active .
To understand the mechanism of inhibitory eect of IFN in the G0/G1-phase of the cell cycle, we and others have earlier shown that IFN-a enhances the expression of underphosphorylated RB protein (pRB) by inhibiting the pRB phosphorylation in human Burkitt's lymphoma Daudi cells (Burke et al., 1992; Kumar and Atlas, 1992; Resnitzky et al., 1992) . We have also demonstrated that IFN-g inhibits the growth of human epidermoid A-431 cells in the G0/G1-phase of the cell cycle (Kumar and Mendelsohn, 1989) . Recently, Harvat and Jetten (1996) have shown that IFN-g, like IFN-a, also enhances the levels of the underphosphorylated pRB form. The inhibition of pRB phosphorylation in IFN-a-treated Daudi cells has been shown to be related to the inhibition of H-1 kinase activity associated with cyclin D1-and Eassociated CDK complexes which contain pRB and E2F , and suppression of DNA-binding activity of E2F (Melamed et al., 1993) . Using prolonged (48 ± 72 h) IFN-a-treatment of Daudi cells, Yamada et al. have shown the downregulation of cyclin H (Yamada et al., 1995) . While this study was in-progress, recent reports have shown a correlation between the induction of p21 WAF1 and inhibition of CDK-2 activity in IFN-a-treated cells (Sangfelt et al., 1997; Hobeika et al., 1997) . Taken together, inspite of our increased understanding of the eect of IFN on the cell cycle during the last few years, the precise mechanism of inhibition of CDKs (CDK-2 and CDK-4) including the potential roles of CKI (p21 WAF1 and p27
Kip1
) and CAK in the growth inhibition by IFNs, remains still unclear.
In the present study, we have investigated the possible roles of CKIs and CAK in the regulation of CDKs in IFN-treated cells. Here, we report that IFN-a inhibits the H-1 kinase activity associated with CDK2 or CDK-4 without any change in its expression. The inhibitory eects of IFN-a on CDKs activities were inpart due to induction of expression of p21 WAF1 (but not p27 Kip1 ) as its immunodepletion restored CDK-associated H-1 kinase activity. In addition, we have now shown that IFN-g induces expression of both p21 WAF1 and p27
, and inhibited the kinase activity associated with CDKs. It was observed that IFN-g inhibited CDK-2 and CDK-4 kinase activity due to enhanced interaction with p21 WAF1 and p27 Kip1 , respectively. We also show that immunodepletion of induced CKIs from the inhibitory extracts resulted in the restoration of CAK-mediated activation of CDK-2. This indicates that IFN-induced CKIs prevent the CAK from activating the CDK-2 in IFN-treated cells.
Results

IFN-a inhibits RB protein phosphorylation and CDKassociated H-1 kinase activity
To understand the mechanism of IFN-mediated growth-inhibition of cells in the G0/G1-phase of the cell-cycle, we and others have earlier shown that IFNa-treatment of Daudi cells leads to enhanced expression of under-phosphorylated form of pRB (Kumar and Atlas, 1992; Resnitzky et al., 1992) . To illustrate this eect, Figure 1 shows the kinetics of inhibition of pRB phosphorylation ( Figure 1a ) and inhibition of CDK-2 associated H-1 kinase activity without any eect on CDK-2 expression ( Figure 1b) . Results in Figure 1a show that in exponentially growing cells, we can resolve three dierent electrophoretically migrating forms and IFN-a predominantly inhibits the expression of slowest migrating form ( Figure WAF1 is known to inhibit the H-1 kinase activity associated with CDK-2 or CDK-4 (Clarke, 1995) , we examined the eect of IFN-a on the inhibition of both CDK-2 and CDK-4 kinase activity, and investigated whether depletion of induced p21 WAF1 would have any eect on CDK-2-and CDK-4-associated kinase activity using H-1 as a substrate. Results in Figure 2 also show that IFN-a dierentially inhibited the H-1 kinase activity associated with CDKs as CDK-2-and CDK-4-associated H-1 kinase activities were inhibited by 3 h and 6 h ( Figure 2b , lanes 1 ± 5), respectively. In addition, data in Figure 2b (lanes 6 ± 10) also illustrate that the depletion of p21 WAF1 before immunoprecipitation (IP) with CDKs could partially restore the inhibition of CDKs kinase activity. The observed IFN-a-mediated early inhibition (6 ± 24 h treatment) of CDK-4-associated H-1 kinase activity was not due to the inhibitory eect of CDK-4 expression, as IFN-atreatment did not inhibit the expression of CDK-4 protein upto 24 h treatment ( Figure 2c ). Results in Figure 2d show that the induced p21 WAF1 also interacts with CDK-4, in addition to the reported interaction with CDK-2 (Poon et al., 1993; Matsuoka et al., 1994) . Since the kinetics of restoration (due to depletion of p21
WAF1
) of H-1 activity associated with CDK-2 or We have previously reported (Kumar and Mendelsohn, 1989 ) that IFN-g inhibits the growth of human epidermoid A-431 cells by arresting the cells in the G0/G1-phase of the cell cycle. To investigate the role of CDK inhibitors in IFN-g-mediated growth-inhibition, we examined the expression of p21 WAF1 and p27 Kip1 in A-431 cells treated with IFN-g for dierent lengths of time. Results in Figure 3 indicated that IFN-g inhibits pRB phosphorylation (Figure 3a) , and also induces the expression of p21 WAF1 and p27 Kip1 ( Figure 3b ). As an internal control, the upper part of the p27
Kip1 blot was blotted with an unrelated HSP-70 mAb. To examine whether the expression of p27
Kip1 can be also induced by IFN-a, we examined the eect of IFN-a on p27 Kip , we examined another IFN-g growth-sensitive cell line NB-4 cells (Korutla and . Results indicated that IFN-g-mediated inhibition of pRB phosphorylation (Figure 3d , lanes 1 ± 3) was also associated with the induction of p27 Kip1 ( Figure 3d , lanes 4 ± 6). There was no eect of IFN-a on p27
Kip1 in NB-4 cells (data not shown). In brief, these results demonstrated that IFN-g induces the expression of both p27
Kip1 and p21
.
Eect on IFN-g on CDKs kinase activity
Since treatment with IFN-g was associated with induction of expression of CKI inhibitors, we next examined the eect of IFN-g on H-1 kinase activity associated with CDKs in A-431 cells. As shown in Figure 4a , IFN-g treatment of A-431 cells resulted in the inhibition of both CDK-2 and CDK-4 kinase activity in a time-dependent manner starting at 12 h post-treatment. Since pRB is the preferred in vivo substrate for CDK-4, we also examined the eect of IFN-a on CDK-4-associated kinase activity, using pRB as a substrate (Choubey and Lengyel, 1995) . Treatment with IFN-a inhibited the ability of CDK-4 to phosphorylate pRB in vitro (Figure 4b ). Since IFN-g induced the expression of both p21 WAF1 and p27
Kip1
, we examined the possible contribution of induced CDKinhibitors in the observed inhibition of H-1 kinase activity associated with CDKs by prior immunodepletion of CDK-inhibitor before IP with CDK. Results in Figure 4c demonstrated that immunodepletion of p21 WAF1 but not p27 Kip1 resulted in partial restoration of CDK-2 kinase activity. In contact, immunodepletion of p27
Kip1 but not p21 WAF1 led to partial restoration of CDK-4 kinase activity. Figure 4d show the increased association of p21 WAF1 with CDK-2, and p27 Kip1 with CDK-4 in IFN-g-treated A-431 cells as compared to control untreated cells. Taken together, these observations suggested that IFN-g-induced p21
WAF1 and p27
Kip1 may have preferential interaction with CDK-2 and CDK-4, respectively.
Eect of IFNs on the expression of CDK-7
In addition to CKIs, the activities of CDKs have been shown to be in¯uenced by phosphorylation by CDK-7 (see Introduction). Since we were not able to completely restore the CDK2 H-1 kinase activity by immunodepletion of CKI, we examined the possibility whether CDK-7 could be a potential IFN target using a well-characterized anti-CDK-7 mAb (Tassan et al., 1994) . Figure 5 shows that IFN-a had no inhibitory eect on CDK-7 expression except that we noticed the appearance of a fused band (not resolved fully in this gel, shown by an arrow) of a slightly faster moving band at 24 h post IFN-a-treatment (Figure 5a , lane 5). In lanes 4 ± 6, both HSP-70 and p27
Kip1 were from the same blot
Regulation of CDKs in IFN-treated cells M Mandal et al
Additional experiments indicated that 24 h or longer treatment of Daudi cells with IFN-a is accompanied by appearance of a distinct faster migrating band of CDK-7 as determined by direct blotting (IB) ( Figure  5a , compare lane 7 with 6) or immunoprecipitation (IP) followed by blotting ( Figure 5b , lane 2). Since the activation of CDK-7 has been shown to require binding of a regulatory cyclin H, we examined whether IFN-a-treatment have any eect on the ability of CDK-7 to interact with cyclin H. Sequential blotting of above blot (Figure 5b , lanes 1 and 2) with cyclin H Ab indicated that there was no eect of IFN-a on the CDK-7 interaction with cyclin H (Figure 5b , lanes 1 and 2). However, when cell extracts were blotted with CDK-7 after IP with cyclin H, the amount of CDK-7 bound with cyclin H was decreased in IFN-a-treated Daudi cells (Figure 5b, lanes 3 and 4) . It is possible that the dierences between CDK-7 mAb immunoprecipitates (lanes 1 and 2) and cyclin H immunoprecipitates (lanes 3 and 4) may be due to the fact that CDK-7 mAb immunoprecipitated both free and cyclin Hbound CDK-7, but cyclin H Ab immunoprecipitated only CDK-7 that was bound with cyclin H. Direct blotting of cell extracts with anti-cyclin H Ab demonstrated that IFN-treatment up to 24 h had no eect on cyclin H expression ( Figure 5c, lanes 2 and 3) . However, prolonged 72 h treatment was associated with inhibition of cyclin H (Figure 5c , lane 4), as shown earlier by Yamada et al. (1995) . It was interesting to note that in lanes 2 and 4 (Figure 5b , IFN-a-treated extracts), the appearance of the faster migrating band was at the expense of a slower migrating band in control cell extracts (lanes 1 and 3). We next examined the eect of IFN-g on the expression of CAK in A-431 and NB-4 cells. Results in Figure 5d and e show that treatment of A-431 and NB-4 cells respectively with IFN-g resulted in the appearance of expression of faster migrating form of CDK-7 (shown by an arrow).
IFN-induced CDK-inhibitors prevent CAK from activating CDK-2
Though there was no early eect of IFN on CDK-7 expression, in an attempt to investigate the possible basis of the inhibition of H-1 kinase in IFN-treated A-431 cells, we examined the possibility whether CDKactivating kinase (CAK) is a direct and/or indirect target of IFN-g. CAK was immunoprecipitated from the control and IFN-g-treated A-431 cell extracts and assayed for its ability to activate recombinant GST-CDK2 which in-turn was assayed for histone H-1 kinase activity (CAK assay). Results in Figure 6a Kip1 mAb (lanes 3 and 4). The blot was stripped and reprobed with the indicated CDK mAbs CDK-7 (data not shown). In addition to the immunecomplex CAK assay, we also assayed CAK activity by in-solution method that allows other components of cell lysate to in¯uence the activation of GST-CDK2 by CAK. In contrast to the results from the immunecomplex CAK assay, results in Figure 6a (right panel) indicated that IFN-g treatment was associated with the inhibition CAK activity. As control, GST-beads were treated in an identical manner and there was no eect (data not shown).
Since IFN-g induces expression of CDK-inhibitors, we reasoned that the observed inhibition of in-solution CAK activity in IFN-treated A-431 cell extracts may be due to induced expression of CDK-inhibitors which may prevent CAK from phosphorylating GST-CDK2. Data in Figure 6b show that immunedepletion of p21 WAF1 (lane 4) or p27 Kip1 (lane 5) from the IFN-gtreated (24 h) inhibitory cell extract (lane 3) resulted in partial restoration of CAK activity, suggesting that IFN-induced CDK-inhibitors prevents the activation of GST-CDK2 by CAK.
Discussion
IFNs are potent regulators of cellular proliferation. The growth inhibitory action of IFN is an active process, and involves suppression of the cell cycle progression. Both IFN-a and IFN-g have been shown to arrest human cells in the G0/G1 phase of the cell cycle. Earlier we and others have shown that IFN inhibits pRB protein phosphorylation by inhibiting CDK-2 kinase activity. We have undertaken the present investigation to further delineate the basis of IFN-mediated inhibition of CDK activity by examining the role(s) of pathways such as CDK-inhibitors and CDK activating kinase that control the function of CDKs.
Results presented here demonstrated that treatment of Daudi cells with IFN-a signi®cantly inhibited both CDK2-and CDK4-associated H-1 kinase activity without any eect on its expression, and this was accompanied by in-parallel induction of expression of CDK-inhibitor p21 WAF1 but not p27
Kip1
. Our this view is supported by recent reports showing a correlation between the induction of p21 WAF1 and inhibition of CDK-2 kinase activity in IFN-a-treated cells (Sangfelt et al., 1997; Hobeika et al., 1997;  reported their results while this study was in progress). In the past, Chin et al. have shown the induction of p21 WAF1 mRNA in IFN-g-treated A-431 cells (Chin et al., 1996) . We have also demonstrated that the observed relationship between the induction of p21 WAF1 and inhibition of CDK kinase activity was not causal as immunodepletion of p21 WAF1 from the inhibitory IFN-a-treated extracts restored in-part the H-1 activity associated with CDK-2 or CDK-4. Since one of the wellaccepted function of CDKs is to phosphorylate dierent substrates such as pRB, IFN should not inhibit the growth of cells that are defective in pRB. However, this view may not always be correct as Hobeika et al. (1997) have recently demonstrated both the induction of p21 WAF1 and inhibition of CDK-2 kinase in IFN-a-treated human prostate carcinoma DU-145 cells that are defective in pRB. Possible signi®cance of IFN-a-induced expression of p21 WAF1 in a pRB minus cell line remains to be investigated. It is possible that IFN-a may inhibit the phosphorylation of other members of pRB family such as p130 which is functional in DU-145 cells (Peng et al., 1996) and/ or IFN-a-induced p21 WAF1 could bind to PCNA and block DNA replication.
The ®nding that IFN-a induces the expression of p21 WAF1 while IFN-g induces the expression of both p21 WAF1 and p27 Kip1 , raises a possibility that p21 WAF1 may be regulated by both IFN-a and IFN-g generated signals but p27 Kip1 can be only induced by IFN-g signal(s). It will be important to further explore the possible molecular basis of dierential regulation of CKIs by IFNs, and such eorts are underway. We have also demonstrated that the induced expression of CKIs may have a functional role in IFN-g-treated cells as immunodepletion of induced CKIs from IFNtreated extracts could partially restore the H-1 kinase activity associated with CDKs. We have also provided evidence to suggest that IFN-g-mediated inhibition of CDK2 and CDK4 was due to preferential enhanced interactions with p21 WAF1 and p27 Kip1 , respectively. In brief, our results suggested a regulatory role of IFNinduced CKIs in the observed inhibition of CDKs in IFN-treated cells. However, due to the partial nature of restoration of CDKs kinase activities by immunodepletion of CKIs, our results raise the possibility of involvement of pathway(s) other than CKIs as potential target(s) in IFN-treated cells.
Our observation that treatment of a variety of celltypes with IFN was accompanied by the late appearance of the faster migrating band of CDK-7, is important as it suggests that the modi®ed CDK-7 in IFN-treated cells may aect its ability to interact with other proteins in multiprotein complexes such as p36/ MAT-1 (Adamczewski et al., 1996) . Since CAK has been shown to be responsible for the C-terminal domain (CTD) kinase activity associated with a multiprotein transcription factor complex TFIIH (Feaver et al., 1994) , it is possible that IFN-mediated appearance of the faster migrating CAK form may in¯uence the CTD kinase activity due to possible modulation of interactions between components of CAK (CDK-7, cyclin H and p36/MAT1) of TFIIH (p89 and p62). (Devault et al., 1995) . Further investigations are required to examine these possibilities.
Another notable ®nding of this study was the indirect inhibitory eect of IFNs on CAK activity. Although recent studies have demonstrated the induction of p21 WAF1 by IFN-a but the mechanism through which CDK-inhibitors inhibit CDK in IFNtreated cells remains poorly understood. Since activation of CDKs requires an essential phosphorylation step by CAK, we therefore examined the hypothesis that IFN-induced CDK-inhibitors may interfere with the activation of CDK by CAK. In agreement with this view, our results have shown that the presence of a CAK inhibitor(s) in IFN-treated extracts, and immunodepletion of p21 WAF1 or p27 Kip1 from the inhibitory IFN-treated extracts resulted in part restoration of CAK-mediated activation of CDK-2. Taken together, these results suggested that IFN-induced CDKinhibitors prevent CAK from activating the CDK holoenzyme.
Materials and methods
Cell culture
Human Burkitt's lymphoma Daudi cells (Kumar and Atlas, 1992) and acute promyelocytic leukemia NB-4 cells (Korutla and were grown in RPMI-1640 medium containing 10% fetal bovine medium. Human epidermoid carcinoma A-431 cells (Kumar and Mendelsohn, 1989) were maintained in Dulbecco's modi®ed eagle's medium (DMEM) supplemented with 10% fetal bovine serum. Human recombinant IFN-a 2a (Speci®c activity, 5610 7 IU/mg protein) and recombinant IFN-g (Speci®c activity 4610 6 IU/mg protein) was obtained from the Homan La Roche Inc. and Genentech Inc., respectively.
Cell extracts and immunoblotting
All experiments were performed with cells in logarithmic phase by controlling the plating density. Cells' extracts were prepared as described (Kumar and Atlas, 1992) . Cell lysates containing equal amount of total protein (15 ± 30 mg) were resolved on a 7% (for RB protein) or 10% (for other proteins) SDS ± PAGE, followed by immunoblotting using alkaline phosphatase or 125 I-protein A or ECL method (Mandal et al., 1996) . As an internal control, the same blot was reprobed with an unrelated antibody. Lowmolecular-mass colored markers (Amersham Corp.) were used as molecular weight standards. The following antibodies were used purchased from the Neomarkers, Inc: anti-RB mAb (clone IF8/Rb-1), anti-p21 mAb (clone DCS 60.2), anti-p27 mAb (clone DCS 72.F6), anti-CDK-7 mAb (clone MO 1-1), and anti-HSP70 mAb (clone BMR 22). Anti-CDK2 mAb (clone 55) and anti-CDK4 mAb (clone 97) were from the Transduction Laboratories. Antibody against cyclin H (SC-609) was purchased from the Santa Cruz, Inc. Quantitation of speci®c protein bands was performed by using protein databases scanner (Molecular Dynamics).
Histone H-1 kinase assay Speci®c CDK was immunoprecipitated from 100 mg total protein by using a speci®c Ab as described . Assay of CDK kinase is based on the transfer of 32 P from labeled ATP by CDK kinase to dephosphorylated H-1 histone. The kinase reaction mixture contained 25 mM glycerophosphate pH 7.3, 10 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, 25 mM HEPES pH 7.3, 5 mg of H-1 histone, 100 pmole ATP and 5 mCi [ 32 P]-ATP in a volume of 25 ml. Reaction product was resolved onto a gel, transferred on a nitrocellulose and subjected to autoradiography. Subsequently the blot was immunoblotted with a speci®c CDK Ab to evaluate the immunoprecipitation eciency.
Expression and puri®cation of recombinant proteins
GST-CDK2 and Histidine-tagged Protein A-cyclin A (PAcyclin A) were generous gifts from Randy Poon and described previously (Poon et al., 1993) . GST-CDK2 was expressed in E. coli, cultures were grown up to log phase and expression of recombinant GST-CDK2 was induced with isopropyl-b-D-thiogalactopyranoside (0.1 mM) for 6 h. Cells were lysed, sonicated and centrifuged at 10 000 g for 30 min as described (Poon et al., 1993) . GST-CDK2 was puri®ed from the supernatant using glutathione-Sepharose 4B protein puri®cation kit from the Pharmacia Fine Chemicals as per manufacturer's instructions. Histidine-tagged Protein A-cyclin A (PA-cyclin A) was also expressed in E. coli and puri®ed by NTA-Ni 2+ agarose anity chromatography following a kit from the Qiagen.
CAK Assay
Immumne-complex CAK assay Cell lysates are IP with anti-CDK-7 mAb, immunoprecipitated complexes (source of CDK-7) were washed with 36lysis buer and 36 with CAK kinase buer, resuspended in 50 ml of CAK buer (Poon et al., 1993) , and 0.2 mg of bacterially produced cyclin A and GST-CDK2 in CAK buer containing 1 mM ATP. The mixture was incubated at 228C for 1 h (CAKmediated activation step). Activated cyclin-CDK complexes in the supernatant were recovered onto glutathione-Sepharose beads, washed with kinase buer, and assayed for H-1 kinase activity.
Soluble CAK assay Cell extracts (100 mg protein, source of CDK-7) were mixed with 0.2 mg of bacterially produced cyclin A and GST-CDK-2 in CAK buer containing 1 mM ATP. The mixture was incubated at 228C for 1 h (CAKmediated activation step). Activated cyclin-CDK complexes were recovered onto glutathione-Sepharose beads, washed with kinase buer, and assay for H-1 kinase activity.
